Optimizing Treatment of Patients With Relapsed... - CLL Support

CLL Support

22,368 members38,474 posts

Optimizing Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jm954 profile image
Jm954Administrator
14 Replies

This is a short paper setting out the non trial option for patients needing treatment after a targeted therapy

jnccn.org/view/journals/jnc...

Jackie

Written by
Jm954 profile image
Jm954
Administrator
To view profiles and participate in discussions please or .
Read more about...
14 Replies
cllady01 profile image
cllady01Former Volunteer

Thank you, Jackie. That is a very readable and relatable read.

I hope you are doing well.

johnliston profile image
johnliston

Jackie, I did I/V the first time around and I don't see any reason it shouldn't work the second time. The time limited treatment and combination should inhibit the development of mutations and I haven't seen and data on clonal selection. So someone will have to tell me why it shouldn't work the second time or even the third time.

Except maybe cost.

john

Jm954 profile image
Jm954Administrator in reply to johnliston

I agree :)

alpek profile image
alpek in reply to Jm954

There was an update posted on the captivate trial linked below that discussed Ibrutinib re-treatment response.

"As of April 2022, a total of 12 patients who experienced disease progression following fixed-duration ibrutinib plus venetoclax were retreated with ibrutinib monotherapy. The duration of single-agent ibrutinib retreatment in these patients ranged from 6 months to 32 months. Of the 11 patients determined to response evaluable, 9 were found to have a PR to retreatment, 1 had a PR-L, and 1 achieved stable disease."

onclive.com/view/updated-ca...

annmcgowan profile image
annmcgowan

Thank you Jackie very interesting. Can I ask if this applies to the U.K.? If so are these options open to all of us on the NHS now?

I remain on the Flair trial but will stop in around 18 months. Hope to be part of the static trial but don’t know if it is set up locally yet.

I hope your own health is going well.

Ann

Jm954 profile image
Jm954Administrator in reply to annmcgowan

They are available in England, Scotland and Wales Ann.

STATIC seems to be endlessly delayed :(

annmcgowan profile image
annmcgowan in reply to Jm954

Thank you Jackie. Take care

Ann

CLLerinOz profile image
CLLerinOzAdministratorVolunteer

Thanks, Jackie, What a great summary article. I really liked the easy to follow chart, too.

Follow up treatment choices after targeted therapy for CLL
LeoPa profile image
LeoPa

Isn't Pirtobrutinib a pi3k inhibitor? Isn't that the same as a non covalent BTK inhibitor? I think I'm lost here 🙂

MrMidnight profile image
MrMidnight in reply to LeoPa

As I understand it, Pirtobrutinib (Loxo-305) is a noncovalent BTK inhibitor. Idealalisib is a pi3k inhibitor.

LeoPa profile image
LeoPa in reply to MrMidnight

Thanks!

Justasheet1 profile image
Justasheet1

BTK and PI3K are different pathways for signaling in the B cell.

Pirtobrutinib is more akin to ibrutinib; hence the name.

LeoPa profile image
LeoPa in reply to Justasheet1

Thanks!

Smakwater profile image
Smakwater

Thanks for the read Jackie,

In other data it appears that venetaclax is still weighing well across all measures for front line. From this article it seem to be second to the covalent BTK's for progressive disease/recurrent CLL when venetoclax was the frontline treatment (84% to 72.2% OS). I learned yesterday that it is acceptable for venetaclax to be used as a monotherapy in relapse wherein the probability of TLS is low. What I mean is that if one is treated before the tumor burden progresses, there is no need to be pre treated with obinutuzumab. This would then not be an option for those with high WBC and no other symptoms, rather it would be used for patients with low counts and specific severe symptoms including night sweats, and fatigue.

It sounds to me like there is a building consensus that Ibrutinib is becoming a favorable way to pre treat for venetaclax whether front line or relapse. Although I am not yet swayed to believe that BTK's are better debulking agents than Obinutuzumab, We should all keep an eye on this, because although Obinutuzumab is a very efficacious CLL drug, it is known to deplete healthy B cells as well as the cancer cells.

My personal add is that I am now 44 months from beginning O+V and yesterday I received verification that my Flow Cytometry reveals no CLL. Although the term MRD negative was not expressed, I understood the result to be just that. All of my labs have been within range for the past two years with the exception of IgM being slightly low. My neutrophils have recovered, however, they also are trending on the lower end.

Given that I am unmutated IGHV, I am very pleased to share this result and to offer encouragement to anyone facing treatment.

My problems are now that I am living longer, I have to deal with the other ugly aging challenges.

Cheerio!

JM

You may also like...

Small lymphocytic lymphoma (SLL)

found a great article by the late Professor Hamblin, further reviewed by CLL Topics in patient...

Chronic lymphocytic leukemia

know if I ned to start treatment or wait till I have symptoms The treatment has no chemotherapy in...

Chronic lymphocytic leukemia

enlarged lymphnode was seen under my left arm. After an ultra sound and a needle biopsy I was...

Information on chronic lymphocytic leukemia

Starting treatment next week with a infusion of obinutuzumab for 4 hours twice a week then off 28...

Son diagnosed with Chronic Lymphocytic Leukemia

chemotherapy treatment's, 10 days and we were finally able to go home and continue treatments here...